Dosimetric Approach to Radioactive Iodine Therapy of Differentiated Thyroid Cancer

My personal memory with Prof. Kalevi Kairemo is related to our coworking for biokinetics of radioactive iodine (RAI), and a couple of international conferences organized by him. I presented my data on the dosimetric approach of RAI treatment for differentiated thyroid cancer (DTC) at the conference in Helsinki. We analyzed the data of our work and published a paper. Here I summarize my experience of working with him. In summary, maximum permissible dose (MPD) therapy with dosimetry is effective for a selected group ofhigh-risk DTC patients. Calculation of MPD is feasible either by tracer and therapeutic doses and either by blood clearance method and metaphase analysis of peripheral blood lymphocytes. The use of recombinant thyroidstimulating hormone (rhTSH) changes the biokinetics of RAI. It needs further investigation whether rhTSH can be used for MPD therapy of DTC.